Esperion Therapeutics Intrinsic Stock Value – ESPERION THERAPEUTICS Releases Q2 Earnings Report for 2023 Fiscal Year

August 9, 2023

🌥️Earnings Overview

ESPERION THERAPEUTICS ($NASDAQ:ESPR) released its Q2 earnings report for the 2023 fiscal year on June 30th 2023. Revenue increased to USD 25.8 million, a 36.9% rise compared to the same quarter in the previous year. Net income decreased from -66.3 million to -49.9 million year-over-year.

Share Price

The stock opened at $1.7 and closed at $1.7, representing a 7.6% increase from the previous closing price of $1.6. This increase in the company’s stock was largely due to positive news from the release of the earnings report. This news was well-received by investors as it showed signs of the company’s growth and stability over the past year.

Thus, it is no surprise that the stock saw a 7.6% increase in value following the release of these numbers. Looking ahead, ESPERION THERAPEUTICS is expected to continue to experience growth and stability as long as it continues to produce strong earnings reports. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Esperion Therapeutics. More…

    Total Revenues Net Income Net Margin
    87.91 -222.26 -252.8%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Esperion Therapeutics. More…

    Operations Investing Financing
    -164.41 63.71 66.23
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Esperion Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    234.63 606.6 -3.93
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Esperion Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -25.9% -187.5%
    FCF Margin ROE ROA
    -187.0% 29.4% -43.9%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Esperion Therapeutics Intrinsic Stock Value

    At GoodWhale, we believe in helping people make informed decisions when it comes to investing in stocks. That’s why we have created a powerful financial analysis tool to assess the financials of ESPERION THERAPEUTICS. After running our analysis, we have determined that the intrinsic value of ESPERION THERAPEUTICS shares is around $3.9, based on our proprietary Valuation Line. This means that the current market price of $1.7 represents a 56.5% discount to its intrinsic value. This could be an opportunity for investors to buy ESPERION THERAPEUTICS shares at a discounted price. However, we always recommend doing your own research before investing in any stock to make sure it meets your financial goals. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The competition among Esperion Therapeutics Inc, Intra-Cellular Therapies Inc, Redhill Biopharma Ltd, and Biofrontera Inc is fierce. Each company is vying for a share of the market for treatments for cholesterol and other lipid disorders. Each company has its own unique approach to treatment, and each has its own strengths and weaknesses. The competition among these companies is sure to be fierce, and the winner is likely to be the company that can best utilize its strengths and capitalize on its rivals’ weaknesses.

    – Intra-Cellular Therapies Inc ($NASDAQ:ITCI)

    As of 2022, Intra-Cellular Therapies Inc has a market cap of 4.38B and a Return on Equity of -26.73%. The company focuses on the development of drugs for the treatment of neuropsychiatric disorders.

    – Redhill Biopharma Ltd ($NASDAQ:RDHL)

    Redhill Biopharma Ltd is a biopharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastrointestinal and inflammatory diseases. The company’s market cap is 43.4M as of 2022 and its ROE is -2625.79%. The company’s products include RHB-104, RHB-105, and RHB-106. RHB-104 is in Phase III clinical trials for the treatment of Crohn’s disease and ulcerative colitis. RHB-105 is in Phase II clinical trials for the treatment of Helicobacter pylori infection. RHB-106 is in Phase I clinical trials for the treatment of inflammatory bowel disease.

    – Biofrontera Inc ($NASDAQ:BFRI)

    The company’s market cap is $25.2 million and its ROE is -91.63%. Biofrontera is a pharmaceutical company that focuses on the development and commercialization of dermatological drugs. The company’s lead product is Ameluz, a prescription cream used to treat actinic keratosis, a precancerous skin condition. Biofrontera also markets two over-the-counter products: Effudix, a cream for the treatment of actinic keratosis, and Belixos, a gel for the treatment of superficial skin infections.


    Esperion Therapeutics has released its Q2 earnings report for the 2023 fiscal year. Total revenue has seen an impressive 36.9% increase to USD 25.8 million, while net income was reported at -49.9 million, a decrease from the previous year. This news has had a positive impact on the company’s stock price on the same day, providing a positive signal for investors. Moving forward, investors should analyse Esperion’s financial performance, the company’s products and services, and potential risks associated with the stock before making an investment decision.

    Recent Posts

    Leave a Comment